AC Immune (ACIU) Q3 2026 earnings review
AC Immune extends its cash outlook while Parkinson's vaccine advances
AC Immune, a Swiss biotech developing drugs for brain diseases, cut its cash burn while advancing its wholly-owned drug pipeline. Research spending dropped 25% from a year ago after last year's staff cuts, and collecting a payment from partner Takeda kept cash resources near CHF 74 million. Interim chief executive Martin Zügel highlighted positive trial results for its Parkinson's vaccine and an anti-inflammatory pill, while extending the cash outlook into early 2028.
| Research and development spending | CHF 9.9M -25% from a year ago |
|---|---|
| Total cash and short-term assets | CHF 73.9M CHF 75.4M last quarter |
| Net loss | CHF 8.8M CHF 15.9M a year ago |
| Cash outlook | Extended into Q1 2028 (was Q4 2027) |
⚖️ Verdict: 🟢 Bullish
The story got better because the restructuring is visibly preserving cash while the company's own Parkinson's vaccine cleared US regulatory hurdles. Extending the funding horizon into 2028 gives the drug maker time to reach early 2027 FDA talks without immediate financing pressure. One caution: initial patient data for the anti-inflammatory drug ACI-19764 slipped from the second half of 2026 into early 2027, and the release gave no clinical news on partnered Alzheimer's trials.
The question now is whether the antibodies generated by the ACI-7104 vaccine can slow Parkinson's disease enough to justify a large pivotal trial. Either the upcoming antibody data and FDA meeting clear a path to late-stage testing, or the regulator asks for more mid-stage work first. The antibody binding readout before year-end and the FDA discussions in early 2027 will tell.
🐂 Bull Case
Restructuring Cut Research Spending by a Quarter
AC Immune reorganized its business and cut its staff by about 30% in late 2025 to focus on its best drug candidates. That cost-cutting plan is now saving cash and stretching the company's bank balance further than planned.
Research and development spending fell 24.6% from a year ago to CHF 9.9 million in the third quarter. The biotech company cited "lower personnel and operational spend of CHF 2.2 million" and a CHF 1.9 million drop in early-stage lab work, while spending on human trials rose by CHF 1.0 million.
- Total cash resources: CHF 73.9 million, down just CHF 1.4 million from last quarter
- Accounts receivable collected: CHF 9.9 million by our math, from a Takeda milestone billed in the second quarter
- Underlying quarterly cash burn: about CHF 11.4 million by our math, excluding the Takeda collection
- Cash outlook: enough money to fund operations into the first quarter of 2028
Lower overhead matters because clinical-stage drug makers rely on their cash reserves to reach trial results without selling new shares. Collecting Takeda's payment and spending less on staff allowed AC Immune to extend its funding horizon by one quarter.
What to watch: fourth-quarter cash resources and full-year cash flow in the annual report. Holding quarterly cash burn near CHF 11 million would confirm that the smaller workforce can support the upcoming human trials.
Parkinson's Vaccine Cleared US Regulatory Hurdles
"This quarter was an important period for AC Immune as we saw our pipeline of wholly-owned programs delivering positive clinical results," interim chief executive Martin Zügel said. The lead wholly-owned drug is ACI-7104, an active immunotherapy designed to train the body's immune system to clear alpha-synuclein, a misfolded protein that builds up in the brains of people with Parkinson's disease.
In the first part of its Phase 2 trial in early Parkinson's patients, the treatment triggered an antibody response in 100% of patients after three doses through week 100. The Swiss drug maker also reported "clear antibody penetration into the cerebrospinal fluid (CSF) and preliminary signals for target engagement", alongside early trends linking antibody levels to disease activity measures.
During the quarter, the US Food and Drug Administration cleared AC Immune's application to run human trials in the United States and granted Fast Track status. This matters because AC Immune owns 100% of ACI-7104, so regulatory clearance lets it plan a larger pivotal study or negotiate a partnership from a stronger position.
What to watch: detailed data on how well these antibodies bind to the target protein before year-end, followed by an FDA meeting in early 2027. Clear binding data and an agreed trial design would let the company start the next phase of testing.
Early Brain Drugs Hit Safety and Lab Goals
Beyond its vaccines, AC Immune is developing oral small-molecule drugs that can cross into the brain to stop inflammation and protein clumping. Its lead pill in human testing is ACI-19764, a drug that blocks NLRP3, an inflammatory pathway linked to brain and heart diseases.
In a Phase 1 trial in healthy volunteers, ACI-19764 proved safe across single and multiple doses, crossed into the spinal fluid, and pointed to a low once-daily dose of 10 milligrams or less. In a separate lab programme using its Morphomer small-molecule platform, the biotech group also selected a lead drug candidate that blocks alpha-synuclein clumping inside cells and started preclinical testing.
Confirming that ACI-19764 reaches the human brain at a low daily dose reduces the risk of side effects as testing moves into patients. Advancing an oral alpha-synuclein blocker also gives the developer a second way to treat Parkinson's disease alongside its vaccine.
What to watch: preclinical results for the new Morphomer candidate at an upcoming scientific conference. Strong animal data would support moving the pill toward human trials.
🐻 Bear Case
Patient Data for the Anti-Inflammatory Drug Slipped
Zügel said the company is well positioned across its portfolio, pointing to upcoming results from a Phase 1b trial of ACI-19764. That trial testswhether the anti-inflammatory pill lowers high-sensitivity C-reactive protein (hsCRP), a blood marker of inflammation, in patients with cardiovascular disease risk.
While the healthy volunteer portion finished on time, the patient data slipped out of 2026. Three months ago, AC Immune told investors to expect those patient results in the second half of 2026. Now the company says the trial continues "in patients with cardiovascular disease risk (elevated hsCRP), with initial results expected early in 2027".
A one-quarter delay does not change the drug's science, but it postpones the first proof that ACI-19764 actually reduces inflammation in sick patients rather than just sitting safely in healthy volunteers. The Morphomer alpha-synuclein lead selection also arrived in the third quarter only after slipping from an original first-half 2026 target earlier this year.
What to watch: the initial hsCRP blood marker readout in the first half of 2027. A drop in inflammatory markers would validate the drug's mechanism, while a further delay or weak signal would hurt the small-molecule pipeline.
Partnered Drug Trials Stay Quiet After Delays
AC Immune relies on big pharmaceutical partners—Takeda, Janssen, and Eli Lilly—to fund its largest Alzheimer's disease trials and pay up to $4.5 billion in potential milestones. Those partnerships provide non-dilutive cash, meaning money that does not require selling new shares.
This quarter's release included no clinical updates on any partnered programme. Earlier in 2026, Janssen paused patient recruitment in the Phase 2b trial of anti-Tau vaccine ACI-35 to amend the study protocol. In addition, AC Immune had previously slated 12-month interim results from the AD3 cohort of its ABATE Phase 2 trial for Alzheimer's vaccine ACI-24 (partnered with Takeda) for the first half of 2026, and the third-quarter update does not mention that readout.
Because AC Immune's cash outlook excludes new milestone payments, delays in partnered trials push out the largest potential cash inflows. Furthermore, CHF 80.7 million of deferred revenue sits on the balance sheet waiting for Takeda to exercise or drop its license option on ACI-24.
What to watch: any update on Takeda's option decision for ACI-24 or Janssen's protocol amendment for ACI-35 in the full-year report. Resuming recruitment or advancing ACI-24 would unlock milestone payments.
👓 Other Themes
Board Changes Continue Under Interim Leadership
AC Immune continues to reshape its leadership after co-founder and chief executive Andrea Pfeifer retired in the second quarter. Board chair Martin Zügel still serves as interim chief executive while the board searches for a permanent replacement. On October 2, shareholders elected Tom Graney to the board and the audit and finance committee, while cell-therapy pioneer Carl June stepped down after several years on the board.
💲 Other KPIs
Contract revenue rose from CHF 0.9 million a year ago as AC Immune recognized payments from Takeda for the fourth cohort of the ACI-24 Alzheimer's trial. Revenue fell from CHF 15.1 million last quarter, by our math, because the second quarter included an upfront payment from Eli Lilly.
The quarterly net loss narrowed by 44.8% from CHF 15.9 million a year ago, and basic loss per share improved from CHF 0.16 to CHF 0.13. Higher Takeda contract revenue, a 24.6% reduction in research spending, and CHF 0.8 million in foreign exchange gains drove the improvement.
Overhead costs edged down 1.3% from CHF 3.6 million a year ago and stayed below the CHF 4.2 million spent in the first quarter. Lower staff expenses after last year's layoff were mostly offset by other operating costs.
🔮 Guidance
Raised. AC Immune expects its CHF 73.9 million in cash and short-term financial assets to "provide sufficient capital to last into Q1 2028, excluding potential milestone payments". That extends the company's funding horizon by one quarter compared with the second-quarter plan, following third-quarter research cost cuts and the collection of Takeda's milestone payment.
Unchanged. Having reported week-100 safety and antibody response rates this quarter, the company plans to release further details on how the induced antibodies bind to alpha-synuclein before the end of 2026, followed by FDA discussions in early 2027.
Cut. Initial anti-inflammatory results in patients with cardiovascular risk and elevated hsCRP are now slated for early 2027 rather than the second half of 2026.
❓ Key Questions
Why did the loss per share calculation imply fewer shares?
A net loss of CHF 8.75 million and a basic loss per share of CHF 0.13 imply about 67 million shares by our math, down from 102 million in the first half. The release did not include a share count table to explain the difference.
What is the status of the ACI-24 Alzheimer's trial?
Previous company timelines pointed to 12-month interim results from the AD3 cohort of the Phase 2 ABATE study in the first half of 2026. The third-quarter release gave no clinical update on the Takeda-partnered programme.
Has Janssen resumed recruiting patients for the ACI-35 study?
Partner Janssen paused enrollment in the Phase 2b ReTain Alzheimer's trial in February 2026 to seek a protocol amendment from health authorities. Investors need to know when recruitment will restart.
When will the board name a permanent chief executive?
Board chair Martin Zügel has served as interim chief executive since Andrea Pfeifer retired at the annual meeting in the second quarter, and the company gave no update on the executive search.